The androgen receptor for the radiation oncologist - Abstract

Androgen deprivation therapy is widely used in combination with radiotherapy for the treatment of prostate cancer.

The knowledge of the biology of the androgen axis could help the radiation oncologist to combine both modalities in an efficient way. Moreover, new drugs have recently been approved and their role in combination with radiation needs pre-clinical and clinical studies. This review summarized the main data on the biology of androgen receptor and the potential implications for the physician. Mechanisms of interactions between androgen deprivation therapy and radiotherapy are also presented and discussed.

Written by:
Quero L, Rozet F, Beuzeboc P, Hennequin C.   Are you the author?
Oncologie-radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France; Institut mutualiste Montsouris, 42, boulevard Jourdan, 75014 Paris, France; Institut Curie, 26, rue d'Ulm, 75005 Paris, France.  

Reference: Cancer Radiother. 2015 May;19(3):220-7.
doi: 10.1016/j.canrad.2015.02.008


PubMed Abstract
PMID: 25921704

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe